nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—MPO—prostate cancer	0.486	1	CbGaD
Octreotide—SSTR1—prostate gland—prostate cancer	0.000826	0.409	CbGeAlD
Octreotide—SSTR2—renal system—prostate cancer	0.000479	0.237	CbGeAlD
Octreotide—MPO—epithelium—prostate cancer	0.000195	0.0967	CbGeAlD
Octreotide—MPO—renal system—prostate cancer	0.000181	0.0897	CbGeAlD
Octreotide—MPO—bone marrow—prostate cancer	0.000137	0.0678	CbGeAlD
Octreotide—MPO—testis—prostate cancer	0.000117	0.058	CbGeAlD
Octreotide—MPO—lymph node—prostate cancer	8.49e-05	0.042	CbGeAlD
Octreotide—Vomiting—Mitoxantrone—prostate cancer	4.46e-05	0.000133	CcSEcCtD
Octreotide—Sinusitis—Doxorubicin—prostate cancer	4.45e-05	0.000133	CcSEcCtD
Octreotide—Convulsion—Prednisone—prostate cancer	4.44e-05	0.000132	CcSEcCtD
Octreotide—Visual impairment—Epirubicin—prostate cancer	4.44e-05	0.000132	CcSEcCtD
Octreotide—Hypertension—Prednisone—prostate cancer	4.42e-05	0.000132	CcSEcCtD
Octreotide—Rash—Mitoxantrone—prostate cancer	4.42e-05	0.000132	CcSEcCtD
Octreotide—Dermatitis—Mitoxantrone—prostate cancer	4.42e-05	0.000132	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.42e-05	0.000132	CcSEcCtD
Octreotide—Headache—Mitoxantrone—prostate cancer	4.39e-05	0.000131	CcSEcCtD
Octreotide—Insomnia—Docetaxel—prostate cancer	4.38e-05	0.000131	CcSEcCtD
Octreotide—Myalgia—Prednisone—prostate cancer	4.36e-05	0.00013	CcSEcCtD
Octreotide—Arthralgia—Prednisone—prostate cancer	4.36e-05	0.00013	CcSEcCtD
Octreotide—Paraesthesia—Docetaxel—prostate cancer	4.35e-05	0.00013	CcSEcCtD
Octreotide—Anxiety—Prednisone—prostate cancer	4.35e-05	0.00013	CcSEcCtD
Octreotide—Bradycardia—Doxorubicin—prostate cancer	4.34e-05	0.000129	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.33e-05	0.000129	CcSEcCtD
Octreotide—Dyspnoea—Docetaxel—prostate cancer	4.32e-05	0.000129	CcSEcCtD
Octreotide—Somnolence—Docetaxel—prostate cancer	4.31e-05	0.000129	CcSEcCtD
Octreotide—Discomfort—Prednisone—prostate cancer	4.31e-05	0.000129	CcSEcCtD
Octreotide—Hypersensitivity—Etoposide—prostate cancer	4.3e-05	0.000128	CcSEcCtD
Octreotide—Tinnitus—Epirubicin—prostate cancer	4.29e-05	0.000128	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.28e-05	0.000128	CcSEcCtD
Octreotide—Flushing—Epirubicin—prostate cancer	4.27e-05	0.000127	CcSEcCtD
Octreotide—Cardiac disorder—Epirubicin—prostate cancer	4.27e-05	0.000127	CcSEcCtD
Octreotide—Rhinitis—Doxorubicin—prostate cancer	4.27e-05	0.000127	CcSEcCtD
Octreotide—Dyspepsia—Docetaxel—prostate cancer	4.27e-05	0.000127	CcSEcCtD
Octreotide—Hepatitis—Doxorubicin—prostate cancer	4.26e-05	0.000127	CcSEcCtD
Octreotide—Insomnia—Capecitabine—prostate cancer	4.24e-05	0.000127	CcSEcCtD
Octreotide—Hypoaesthesia—Doxorubicin—prostate cancer	4.24e-05	0.000126	CcSEcCtD
Octreotide—Pharyngitis—Doxorubicin—prostate cancer	4.23e-05	0.000126	CcSEcCtD
Octreotide—Paraesthesia—Capecitabine—prostate cancer	4.21e-05	0.000126	CcSEcCtD
Octreotide—Decreased appetite—Docetaxel—prostate cancer	4.21e-05	0.000126	CcSEcCtD
Octreotide—Oedema peripheral—Doxorubicin—prostate cancer	4.19e-05	0.000125	CcSEcCtD
Octreotide—Gastrointestinal disorder—Docetaxel—prostate cancer	4.19e-05	0.000125	CcSEcCtD
Octreotide—Asthenia—Etoposide—prostate cancer	4.19e-05	0.000125	CcSEcCtD
Octreotide—Dyspnoea—Capecitabine—prostate cancer	4.18e-05	0.000125	CcSEcCtD
Octreotide—Oedema—Prednisone—prostate cancer	4.18e-05	0.000125	CcSEcCtD
Octreotide—Anaphylactic shock—Prednisone—prostate cancer	4.18e-05	0.000125	CcSEcCtD
Octreotide—Fatigue—Docetaxel—prostate cancer	4.18e-05	0.000125	CcSEcCtD
Octreotide—Nausea—Mitoxantrone—prostate cancer	4.17e-05	0.000124	CcSEcCtD
Octreotide—Immune system disorder—Epirubicin—prostate cancer	4.16e-05	0.000124	CcSEcCtD
Octreotide—Infection—Prednisone—prostate cancer	4.15e-05	0.000124	CcSEcCtD
Octreotide—Constipation—Docetaxel—prostate cancer	4.15e-05	0.000124	CcSEcCtD
Octreotide—Pain—Docetaxel—prostate cancer	4.15e-05	0.000124	CcSEcCtD
Octreotide—Dyspepsia—Capecitabine—prostate cancer	4.13e-05	0.000123	CcSEcCtD
Octreotide—Pruritus—Etoposide—prostate cancer	4.13e-05	0.000123	CcSEcCtD
Octreotide—Shock—Prednisone—prostate cancer	4.11e-05	0.000123	CcSEcCtD
Octreotide—Arrhythmia—Epirubicin—prostate cancer	4.11e-05	0.000123	CcSEcCtD
Octreotide—Visual impairment—Doxorubicin—prostate cancer	4.1e-05	0.000122	CcSEcCtD
Octreotide—Nervous system disorder—Prednisone—prostate cancer	4.1e-05	0.000122	CcSEcCtD
Octreotide—Tachycardia—Prednisone—prostate cancer	4.08e-05	0.000122	CcSEcCtD
Octreotide—Decreased appetite—Capecitabine—prostate cancer	4.08e-05	0.000122	CcSEcCtD
Octreotide—Alopecia—Epirubicin—prostate cancer	4.07e-05	0.000121	CcSEcCtD
Octreotide—Skin disorder—Prednisone—prostate cancer	4.06e-05	0.000121	CcSEcCtD
Octreotide—Gastrointestinal disorder—Capecitabine—prostate cancer	4.05e-05	0.000121	CcSEcCtD
Octreotide—Fatigue—Capecitabine—prostate cancer	4.05e-05	0.000121	CcSEcCtD
Octreotide—Hyperhidrosis—Prednisone—prostate cancer	4.04e-05	0.000121	CcSEcCtD
Octreotide—Mental disorder—Epirubicin—prostate cancer	4.03e-05	0.00012	CcSEcCtD
Octreotide—Pain—Capecitabine—prostate cancer	4.01e-05	0.00012	CcSEcCtD
Octreotide—Constipation—Capecitabine—prostate cancer	4.01e-05	0.00012	CcSEcCtD
Octreotide—Erythema—Epirubicin—prostate cancer	4.01e-05	0.000119	CcSEcCtD
Octreotide—Malnutrition—Epirubicin—prostate cancer	4.01e-05	0.000119	CcSEcCtD
Octreotide—Feeling abnormal—Docetaxel—prostate cancer	3.99e-05	0.000119	CcSEcCtD
Octreotide—Diarrhoea—Etoposide—prostate cancer	3.99e-05	0.000119	CcSEcCtD
Octreotide—Anorexia—Prednisone—prostate cancer	3.99e-05	0.000119	CcSEcCtD
Octreotide—Tinnitus—Doxorubicin—prostate cancer	3.97e-05	0.000118	CcSEcCtD
Octreotide—Gastrointestinal pain—Docetaxel—prostate cancer	3.96e-05	0.000118	CcSEcCtD
Octreotide—Cardiac disorder—Doxorubicin—prostate cancer	3.95e-05	0.000118	CcSEcCtD
Octreotide—Flushing—Doxorubicin—prostate cancer	3.95e-05	0.000118	CcSEcCtD
Octreotide—Flatulence—Epirubicin—prostate cancer	3.95e-05	0.000118	CcSEcCtD
Octreotide—Tension—Epirubicin—prostate cancer	3.93e-05	0.000117	CcSEcCtD
Octreotide—Nervousness—Epirubicin—prostate cancer	3.89e-05	0.000116	CcSEcCtD
Octreotide—Back pain—Epirubicin—prostate cancer	3.88e-05	0.000116	CcSEcCtD
Octreotide—Feeling abnormal—Capecitabine—prostate cancer	3.87e-05	0.000115	CcSEcCtD
Octreotide—Dizziness—Etoposide—prostate cancer	3.86e-05	0.000115	CcSEcCtD
Octreotide—Muscle spasms—Epirubicin—prostate cancer	3.85e-05	0.000115	CcSEcCtD
Octreotide—Immune system disorder—Doxorubicin—prostate cancer	3.85e-05	0.000115	CcSEcCtD
Octreotide—Gastrointestinal pain—Capecitabine—prostate cancer	3.84e-05	0.000114	CcSEcCtD
Octreotide—Body temperature increased—Docetaxel—prostate cancer	3.83e-05	0.000114	CcSEcCtD
Octreotide—Abdominal pain—Docetaxel—prostate cancer	3.83e-05	0.000114	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Prednisone—prostate cancer	3.81e-05	0.000114	CcSEcCtD
Octreotide—Arrhythmia—Doxorubicin—prostate cancer	3.8e-05	0.000113	CcSEcCtD
Octreotide—Insomnia—Prednisone—prostate cancer	3.78e-05	0.000113	CcSEcCtD
Octreotide—Vision blurred—Epirubicin—prostate cancer	3.78e-05	0.000113	CcSEcCtD
Octreotide—Alopecia—Doxorubicin—prostate cancer	3.76e-05	0.000112	CcSEcCtD
Octreotide—Paraesthesia—Prednisone—prostate cancer	3.75e-05	0.000112	CcSEcCtD
Octreotide—Mental disorder—Doxorubicin—prostate cancer	3.73e-05	0.000111	CcSEcCtD
Octreotide—Urticaria—Capecitabine—prostate cancer	3.73e-05	0.000111	CcSEcCtD
Octreotide—Ill-defined disorder—Epirubicin—prostate cancer	3.72e-05	0.000111	CcSEcCtD
Octreotide—Abdominal pain—Capecitabine—prostate cancer	3.71e-05	0.000111	CcSEcCtD
Octreotide—Body temperature increased—Capecitabine—prostate cancer	3.71e-05	0.000111	CcSEcCtD
Octreotide—Vomiting—Etoposide—prostate cancer	3.71e-05	0.000111	CcSEcCtD
Octreotide—Erythema—Doxorubicin—prostate cancer	3.71e-05	0.000111	CcSEcCtD
Octreotide—Malnutrition—Doxorubicin—prostate cancer	3.71e-05	0.000111	CcSEcCtD
Octreotide—Anaemia—Epirubicin—prostate cancer	3.7e-05	0.00011	CcSEcCtD
Octreotide—Agitation—Epirubicin—prostate cancer	3.68e-05	0.00011	CcSEcCtD
Octreotide—Dyspepsia—Prednisone—prostate cancer	3.68e-05	0.00011	CcSEcCtD
Octreotide—Rash—Etoposide—prostate cancer	3.68e-05	0.00011	CcSEcCtD
Octreotide—Dermatitis—Etoposide—prostate cancer	3.67e-05	0.00011	CcSEcCtD
Octreotide—Headache—Etoposide—prostate cancer	3.65e-05	0.000109	CcSEcCtD
Octreotide—Flatulence—Doxorubicin—prostate cancer	3.65e-05	0.000109	CcSEcCtD
Octreotide—Tension—Doxorubicin—prostate cancer	3.64e-05	0.000108	CcSEcCtD
Octreotide—Decreased appetite—Prednisone—prostate cancer	3.63e-05	0.000108	CcSEcCtD
Octreotide—Malaise—Epirubicin—prostate cancer	3.61e-05	0.000108	CcSEcCtD
Octreotide—Fatigue—Prednisone—prostate cancer	3.6e-05	0.000107	CcSEcCtD
Octreotide—Nervousness—Doxorubicin—prostate cancer	3.6e-05	0.000107	CcSEcCtD
Octreotide—Vertigo—Epirubicin—prostate cancer	3.6e-05	0.000107	CcSEcCtD
Octreotide—Syncope—Epirubicin—prostate cancer	3.59e-05	0.000107	CcSEcCtD
Octreotide—Back pain—Doxorubicin—prostate cancer	3.59e-05	0.000107	CcSEcCtD
Octreotide—Constipation—Prednisone—prostate cancer	3.58e-05	0.000107	CcSEcCtD
Octreotide—Hypersensitivity—Docetaxel—prostate cancer	3.57e-05	0.000107	CcSEcCtD
Octreotide—Muscle spasms—Doxorubicin—prostate cancer	3.56e-05	0.000106	CcSEcCtD
Octreotide—Palpitations—Epirubicin—prostate cancer	3.54e-05	0.000106	CcSEcCtD
Octreotide—Loss of consciousness—Epirubicin—prostate cancer	3.52e-05	0.000105	CcSEcCtD
Octreotide—Cough—Epirubicin—prostate cancer	3.5e-05	0.000104	CcSEcCtD
Octreotide—Vision blurred—Doxorubicin—prostate cancer	3.49e-05	0.000104	CcSEcCtD
Octreotide—Asthenia—Docetaxel—prostate cancer	3.48e-05	0.000104	CcSEcCtD
Octreotide—Convulsion—Epirubicin—prostate cancer	3.47e-05	0.000104	CcSEcCtD
Octreotide—Nausea—Etoposide—prostate cancer	3.46e-05	0.000103	CcSEcCtD
Octreotide—Hypertension—Epirubicin—prostate cancer	3.46e-05	0.000103	CcSEcCtD
Octreotide—Hypersensitivity—Capecitabine—prostate cancer	3.46e-05	0.000103	CcSEcCtD
Octreotide—Feeling abnormal—Prednisone—prostate cancer	3.45e-05	0.000103	CcSEcCtD
Octreotide—Ill-defined disorder—Doxorubicin—prostate cancer	3.44e-05	0.000103	CcSEcCtD
Octreotide—Pruritus—Docetaxel—prostate cancer	3.43e-05	0.000102	CcSEcCtD
Octreotide—Anaemia—Doxorubicin—prostate cancer	3.43e-05	0.000102	CcSEcCtD
Octreotide—Gastrointestinal pain—Prednisone—prostate cancer	3.42e-05	0.000102	CcSEcCtD
Octreotide—Arthralgia—Epirubicin—prostate cancer	3.41e-05	0.000102	CcSEcCtD
Octreotide—Myalgia—Epirubicin—prostate cancer	3.41e-05	0.000102	CcSEcCtD
Octreotide—Chest pain—Epirubicin—prostate cancer	3.41e-05	0.000102	CcSEcCtD
Octreotide—Agitation—Doxorubicin—prostate cancer	3.41e-05	0.000102	CcSEcCtD
Octreotide—Anxiety—Epirubicin—prostate cancer	3.4e-05	0.000101	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.39e-05	0.000101	CcSEcCtD
Octreotide—Discomfort—Epirubicin—prostate cancer	3.37e-05	0.000101	CcSEcCtD
Octreotide—Asthenia—Capecitabine—prostate cancer	3.37e-05	0.0001	CcSEcCtD
Octreotide—Malaise—Doxorubicin—prostate cancer	3.34e-05	9.97e-05	CcSEcCtD
Octreotide—Dry mouth—Epirubicin—prostate cancer	3.34e-05	9.95e-05	CcSEcCtD
Octreotide—Vertigo—Doxorubicin—prostate cancer	3.33e-05	9.93e-05	CcSEcCtD
Octreotide—Syncope—Doxorubicin—prostate cancer	3.32e-05	9.91e-05	CcSEcCtD
Octreotide—Urticaria—Prednisone—prostate cancer	3.32e-05	9.91e-05	CcSEcCtD
Octreotide—Pruritus—Capecitabine—prostate cancer	3.32e-05	9.9e-05	CcSEcCtD
Octreotide—Diarrhoea—Docetaxel—prostate cancer	3.32e-05	9.89e-05	CcSEcCtD
Octreotide—Body temperature increased—Prednisone—prostate cancer	3.3e-05	9.86e-05	CcSEcCtD
Octreotide—Abdominal pain—Prednisone—prostate cancer	3.3e-05	9.86e-05	CcSEcCtD
Octreotide—Palpitations—Doxorubicin—prostate cancer	3.28e-05	9.77e-05	CcSEcCtD
Octreotide—Oedema—Epirubicin—prostate cancer	3.27e-05	9.75e-05	CcSEcCtD
Octreotide—Anaphylactic shock—Epirubicin—prostate cancer	3.27e-05	9.75e-05	CcSEcCtD
Octreotide—Loss of consciousness—Doxorubicin—prostate cancer	3.26e-05	9.72e-05	CcSEcCtD
Octreotide—Infection—Epirubicin—prostate cancer	3.25e-05	9.69e-05	CcSEcCtD
Octreotide—Cough—Doxorubicin—prostate cancer	3.23e-05	9.65e-05	CcSEcCtD
Octreotide—Shock—Epirubicin—prostate cancer	3.22e-05	9.59e-05	CcSEcCtD
Octreotide—Convulsion—Doxorubicin—prostate cancer	3.21e-05	9.58e-05	CcSEcCtD
Octreotide—Diarrhoea—Capecitabine—prostate cancer	3.21e-05	9.58e-05	CcSEcCtD
Octreotide—Nervous system disorder—Epirubicin—prostate cancer	3.21e-05	9.56e-05	CcSEcCtD
Octreotide—Dizziness—Docetaxel—prostate cancer	3.21e-05	9.56e-05	CcSEcCtD
Octreotide—Thrombocytopenia—Epirubicin—prostate cancer	3.2e-05	9.55e-05	CcSEcCtD
Octreotide—Hypertension—Doxorubicin—prostate cancer	3.2e-05	9.55e-05	CcSEcCtD
Octreotide—Tachycardia—Epirubicin—prostate cancer	3.19e-05	9.52e-05	CcSEcCtD
Octreotide—Skin disorder—Epirubicin—prostate cancer	3.18e-05	9.47e-05	CcSEcCtD
Octreotide—Hyperhidrosis—Epirubicin—prostate cancer	3.16e-05	9.43e-05	CcSEcCtD
Octreotide—Chest pain—Doxorubicin—prostate cancer	3.16e-05	9.41e-05	CcSEcCtD
Octreotide—Arthralgia—Doxorubicin—prostate cancer	3.16e-05	9.41e-05	CcSEcCtD
Octreotide—Myalgia—Doxorubicin—prostate cancer	3.16e-05	9.41e-05	CcSEcCtD
Octreotide—Anxiety—Doxorubicin—prostate cancer	3.15e-05	9.38e-05	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.13e-05	9.35e-05	CcSEcCtD
Octreotide—Discomfort—Doxorubicin—prostate cancer	3.12e-05	9.3e-05	CcSEcCtD
Octreotide—Anorexia—Epirubicin—prostate cancer	3.12e-05	9.3e-05	CcSEcCtD
Octreotide—Dizziness—Capecitabine—prostate cancer	3.1e-05	9.26e-05	CcSEcCtD
Octreotide—Dry mouth—Doxorubicin—prostate cancer	3.09e-05	9.21e-05	CcSEcCtD
Octreotide—Vomiting—Docetaxel—prostate cancer	3.08e-05	9.19e-05	CcSEcCtD
Octreotide—Hypersensitivity—Prednisone—prostate cancer	3.08e-05	9.19e-05	CcSEcCtD
Octreotide—Rash—Docetaxel—prostate cancer	3.06e-05	9.12e-05	CcSEcCtD
Octreotide—Dermatitis—Docetaxel—prostate cancer	3.05e-05	9.11e-05	CcSEcCtD
Octreotide—Headache—Docetaxel—prostate cancer	3.04e-05	9.06e-05	CcSEcCtD
Octreotide—Oedema—Doxorubicin—prostate cancer	3.03e-05	9.02e-05	CcSEcCtD
Octreotide—Anaphylactic shock—Doxorubicin—prostate cancer	3.03e-05	9.02e-05	CcSEcCtD
Octreotide—Infection—Doxorubicin—prostate cancer	3.01e-05	8.96e-05	CcSEcCtD
Octreotide—Asthenia—Prednisone—prostate cancer	3e-05	8.95e-05	CcSEcCtD
Octreotide—Vomiting—Capecitabine—prostate cancer	2.98e-05	8.9e-05	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.98e-05	8.88e-05	CcSEcCtD
Octreotide—Shock—Doxorubicin—prostate cancer	2.98e-05	8.88e-05	CcSEcCtD
Octreotide—Nervous system disorder—Doxorubicin—prostate cancer	2.97e-05	8.85e-05	CcSEcCtD
Octreotide—Thrombocytopenia—Doxorubicin—prostate cancer	2.96e-05	8.83e-05	CcSEcCtD
Octreotide—Rash—Capecitabine—prostate cancer	2.96e-05	8.83e-05	CcSEcCtD
Octreotide—Pruritus—Prednisone—prostate cancer	2.96e-05	8.82e-05	CcSEcCtD
Octreotide—Insomnia—Epirubicin—prostate cancer	2.96e-05	8.82e-05	CcSEcCtD
Octreotide—Dermatitis—Capecitabine—prostate cancer	2.96e-05	8.82e-05	CcSEcCtD
Octreotide—Tachycardia—Doxorubicin—prostate cancer	2.95e-05	8.81e-05	CcSEcCtD
Octreotide—Headache—Capecitabine—prostate cancer	2.94e-05	8.77e-05	CcSEcCtD
Octreotide—Skin disorder—Doxorubicin—prostate cancer	2.94e-05	8.76e-05	CcSEcCtD
Octreotide—Paraesthesia—Epirubicin—prostate cancer	2.94e-05	8.76e-05	CcSEcCtD
Octreotide—Hyperhidrosis—Doxorubicin—prostate cancer	2.92e-05	8.72e-05	CcSEcCtD
Octreotide—Dyspnoea—Epirubicin—prostate cancer	2.92e-05	8.69e-05	CcSEcCtD
Octreotide—Somnolence—Epirubicin—prostate cancer	2.91e-05	8.67e-05	CcSEcCtD
Octreotide—Anorexia—Doxorubicin—prostate cancer	2.88e-05	8.6e-05	CcSEcCtD
Octreotide—Nausea—Docetaxel—prostate cancer	2.88e-05	8.59e-05	CcSEcCtD
Octreotide—Dyspepsia—Epirubicin—prostate cancer	2.88e-05	8.58e-05	CcSEcCtD
Octreotide—Diarrhoea—Prednisone—prostate cancer	2.86e-05	8.53e-05	CcSEcCtD
Octreotide—Decreased appetite—Epirubicin—prostate cancer	2.84e-05	8.48e-05	CcSEcCtD
Octreotide—Gastrointestinal disorder—Epirubicin—prostate cancer	2.82e-05	8.42e-05	CcSEcCtD
Octreotide—Fatigue—Epirubicin—prostate cancer	2.82e-05	8.41e-05	CcSEcCtD
Octreotide—Pain—Epirubicin—prostate cancer	2.8e-05	8.34e-05	CcSEcCtD
Octreotide—Constipation—Epirubicin—prostate cancer	2.8e-05	8.34e-05	CcSEcCtD
Octreotide—Nausea—Capecitabine—prostate cancer	2.79e-05	8.31e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—NOS3—prostate cancer	2.77e-05	0.000157	CbGpPWpGaD
Octreotide—Dizziness—Prednisone—prostate cancer	2.76e-05	8.25e-05	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.76e-05	8.22e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—HIF1A—prostate cancer	2.75e-05	0.000156	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—ITGB3—prostate cancer	2.75e-05	0.000156	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—KDR—prostate cancer	2.75e-05	0.000156	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IGF1R—prostate cancer	2.74e-05	0.000155	CbGpPWpGaD
Octreotide—Insomnia—Doxorubicin—prostate cancer	2.74e-05	8.16e-05	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—CXCL8—prostate cancer	2.73e-05	0.000154	CbGpPWpGaD
Octreotide—Paraesthesia—Doxorubicin—prostate cancer	2.72e-05	8.1e-05	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—JAK2—prostate cancer	2.71e-05	0.000154	CbGpPWpGaD
Octreotide—Dyspnoea—Doxorubicin—prostate cancer	2.7e-05	8.04e-05	CcSEcCtD
Octreotide—Feeling abnormal—Epirubicin—prostate cancer	2.69e-05	8.04e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—JAK2—prostate cancer	2.69e-05	0.000153	CbGpPWpGaD
Octreotide—Somnolence—Doxorubicin—prostate cancer	2.69e-05	8.02e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—LEP—prostate cancer	2.69e-05	0.000152	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—CXCL8—prostate cancer	2.68e-05	0.000152	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—ESR1—prostate cancer	2.68e-05	0.000152	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Epirubicin—prostate cancer	2.67e-05	7.97e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—ERBB3—prostate cancer	2.66e-05	0.000151	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CAV1—prostate cancer	2.66e-05	0.000151	CbGpPWpGaD
Octreotide—Dyspepsia—Doxorubicin—prostate cancer	2.66e-05	7.94e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—FGFR2—prostate cancer	2.66e-05	0.000151	CbGpPWpGaD
Octreotide—Vomiting—Prednisone—prostate cancer	2.66e-05	7.93e-05	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—PIK3CA—prostate cancer	2.64e-05	0.00015	CbGpPWpGaD
Octreotide—Rash—Prednisone—prostate cancer	2.64e-05	7.86e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—KDR—prostate cancer	2.63e-05	0.000149	CbGpPWpGaD
Octreotide—Dermatitis—Prednisone—prostate cancer	2.63e-05	7.85e-05	CcSEcCtD
Octreotide—Decreased appetite—Doxorubicin—prostate cancer	2.63e-05	7.84e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—MDM2—prostate cancer	2.63e-05	0.000149	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—LPL—prostate cancer	2.63e-05	0.000149	CbGpPWpGaD
Octreotide—Headache—Prednisone—prostate cancer	2.62e-05	7.81e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—BAD—prostate cancer	2.61e-05	0.000148	CbGpPWpGaD
Octreotide—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.61e-05	7.79e-05	CcSEcCtD
Octreotide—Fatigue—Doxorubicin—prostate cancer	2.61e-05	7.78e-05	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—IL2—prostate cancer	2.61e-05	0.000148	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PDGFRB—prostate cancer	2.6e-05	0.000147	CbGpPWpGaD
Octreotide—Urticaria—Epirubicin—prostate cancer	2.6e-05	7.75e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—ERBB2—prostate cancer	2.59e-05	0.000147	CbGpPWpGaD
Octreotide—Constipation—Doxorubicin—prostate cancer	2.59e-05	7.72e-05	CcSEcCtD
Octreotide—Pain—Doxorubicin—prostate cancer	2.59e-05	7.72e-05	CcSEcCtD
Octreotide—Body temperature increased—Epirubicin—prostate cancer	2.58e-05	7.71e-05	CcSEcCtD
Octreotide—Abdominal pain—Epirubicin—prostate cancer	2.58e-05	7.71e-05	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—PIK3CB—prostate cancer	2.58e-05	0.000146	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—ESR1—prostate cancer	2.57e-05	0.000145	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—IL2—prostate cancer	2.56e-05	0.000145	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PIK3CB—prostate cancer	2.56e-05	0.000145	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TERT—prostate cancer	2.55e-05	0.000145	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—ITGB3—prostate cancer	2.54e-05	0.000144	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—APC—prostate cancer	2.53e-05	0.000143	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PIK3CG—prostate cancer	2.53e-05	0.000143	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—BAD—prostate cancer	2.51e-05	0.000142	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EGF—prostate cancer	2.5e-05	0.000142	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IRS1—prostate cancer	2.5e-05	0.000142	CbGpPWpGaD
Octreotide—Feeling abnormal—Doxorubicin—prostate cancer	2.49e-05	7.44e-05	CcSEcCtD
Octreotide—Nausea—Prednisone—prostate cancer	2.48e-05	7.41e-05	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—CXCL8—prostate cancer	2.48e-05	0.00014	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Doxorubicin—prostate cancer	2.47e-05	7.38e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—ERBB3—prostate cancer	2.46e-05	0.000139	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CXCL8—prostate cancer	2.46e-05	0.000139	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—FGFR2—prostate cancer	2.46e-05	0.000139	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—HIF1A—prostate cancer	2.44e-05	0.000138	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—GSK3B—prostate cancer	2.43e-05	0.000138	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—APC—prostate cancer	2.43e-05	0.000137	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PIK3CG—prostate cancer	2.43e-05	0.000137	CbGpPWpGaD
Octreotide—Hypersensitivity—Epirubicin—prostate cancer	2.41e-05	7.18e-05	CcSEcCtD
Octreotide—Urticaria—Doxorubicin—prostate cancer	2.4e-05	7.17e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—CDKN1B—prostate cancer	2.4e-05	0.000136	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EGF—prostate cancer	2.4e-05	0.000136	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—IRS1—prostate cancer	2.4e-05	0.000136	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—INS—prostate cancer	2.4e-05	0.000136	CbGpPWpGaD
Octreotide—Body temperature increased—Doxorubicin—prostate cancer	2.39e-05	7.13e-05	CcSEcCtD
Octreotide—Abdominal pain—Doxorubicin—prostate cancer	2.39e-05	7.13e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—LEP—prostate cancer	2.38e-05	0.000135	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—AKT1—prostate cancer	2.38e-05	0.000135	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—IL2—prostate cancer	2.37e-05	0.000134	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CAV1—prostate cancer	2.36e-05	0.000134	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TERT—prostate cancer	2.36e-05	0.000133	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CASP3—prostate cancer	2.35e-05	0.000133	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—IL2—prostate cancer	2.35e-05	0.000133	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CREBBP—prostate cancer	2.35e-05	0.000133	CbGpPWpGaD
Octreotide—Asthenia—Epirubicin—prostate cancer	2.35e-05	7e-05	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—IL6—prostate cancer	2.34e-05	0.000132	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—KDR—prostate cancer	2.34e-05	0.000132	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—GSK3B—prostate cancer	2.33e-05	0.000132	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IGF1—prostate cancer	2.32e-05	0.000131	CbGpPWpGaD
Octreotide—Pruritus—Epirubicin—prostate cancer	2.31e-05	6.9e-05	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—EGFR—prostate cancer	2.31e-05	0.000131	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—INS—prostate cancer	2.3e-05	0.00013	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CCND1—prostate cancer	2.29e-05	0.00013	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—ESR1—prostate cancer	2.28e-05	0.000129	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CTNNB1—prostate cancer	2.27e-05	0.000128	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—HIF1A—prostate cancer	2.25e-05	0.000128	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CREBBP—prostate cancer	2.25e-05	0.000127	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MAP2K1—prostate cancer	2.24e-05	0.000127	CbGpPWpGaD
Octreotide—Diarrhoea—Epirubicin—prostate cancer	2.24e-05	6.67e-05	CcSEcCtD
Octreotide—Hypersensitivity—Doxorubicin—prostate cancer	2.23e-05	6.65e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—PIK3CD—prostate cancer	2.22e-05	0.000126	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MMP9—prostate cancer	2.22e-05	0.000126	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—BAD—prostate cancer	2.22e-05	0.000126	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—IGF1—prostate cancer	2.22e-05	0.000126	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CDKN1A—prostate cancer	2.22e-05	0.000125	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PTEN—prostate cancer	2.21e-05	0.000125	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—EGFR—prostate cancer	2.21e-05	0.000125	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—PIK3CA—prostate cancer	2.2e-05	0.000125	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—SERPINE1—prostate cancer	2.2e-05	0.000125	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—LEP—prostate cancer	2.2e-05	0.000125	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CAV1—prostate cancer	2.18e-05	0.000123	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—KRAS—prostate cancer	2.18e-05	0.000123	CbGpPWpGaD
Octreotide—Asthenia—Doxorubicin—prostate cancer	2.17e-05	6.47e-05	CcSEcCtD
Octreotide—Dizziness—Epirubicin—prostate cancer	2.16e-05	6.45e-05	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—AKT1—prostate cancer	2.16e-05	0.000122	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—KDR—prostate cancer	2.16e-05	0.000122	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—APC—prostate cancer	2.15e-05	0.000122	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PIK3CG—prostate cancer	2.15e-05	0.000122	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MAP2K1—prostate cancer	2.15e-05	0.000122	CbGpPWpGaD
Octreotide—Pruritus—Doxorubicin—prostate cancer	2.14e-05	6.38e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—PIK3CD—prostate cancer	2.13e-05	0.000121	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—FGF2—prostate cancer	2.13e-05	0.000121	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EGF—prostate cancer	2.13e-05	0.00012	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IRS1—prostate cancer	2.13e-05	0.00012	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—PIK3CA—prostate cancer	2.11e-05	0.00012	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—SERPINE1—prostate cancer	2.11e-05	0.000119	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—EP300—prostate cancer	2.11e-05	0.000119	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—ESR1—prostate cancer	2.1e-05	0.000119	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—NOS3—prostate cancer	2.1e-05	0.000119	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—KRAS—prostate cancer	2.09e-05	0.000118	CbGpPWpGaD
Octreotide—Vomiting—Epirubicin—prostate cancer	2.08e-05	6.2e-05	CcSEcCtD
Octreotide—Diarrhoea—Doxorubicin—prostate cancer	2.07e-05	6.17e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—GSK3B—prostate cancer	2.06e-05	0.000117	CbGpPWpGaD
Octreotide—Rash—Epirubicin—prostate cancer	2.06e-05	6.15e-05	CcSEcCtD
Octreotide—Dermatitis—Epirubicin—prostate cancer	2.06e-05	6.14e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—BAD—prostate cancer	2.05e-05	0.000116	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—SRC—prostate cancer	2.05e-05	0.000116	CbGpPWpGaD
Octreotide—Headache—Epirubicin—prostate cancer	2.05e-05	6.11e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—FGF2—prostate cancer	2.04e-05	0.000116	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—JAK2—prostate cancer	2.04e-05	0.000116	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—INS—prostate cancer	2.04e-05	0.000115	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NOS3—prostate cancer	2.01e-05	0.000114	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—PIK3CA—prostate cancer	2e-05	0.000113	CbGpPWpGaD
Octreotide—Dizziness—Doxorubicin—prostate cancer	2e-05	5.97e-05	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—VEGFA—prostate cancer	2e-05	0.000113	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CREBBP—prostate cancer	2e-05	0.000113	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MDM2—prostate cancer	1.99e-05	0.000113	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3CG—prostate cancer	1.99e-05	0.000112	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—APC—prostate cancer	1.99e-05	0.000112	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—STAT3—prostate cancer	1.98e-05	0.000112	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IGF1—prostate cancer	1.97e-05	0.000112	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—ERBB2—prostate cancer	1.97e-05	0.000111	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—EGF—prostate cancer	1.96e-05	0.000111	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IRS1—prostate cancer	1.96e-05	0.000111	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—EGFR—prostate cancer	1.96e-05	0.000111	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—JAK2—prostate cancer	1.96e-05	0.000111	CbGpPWpGaD
Octreotide—Nausea—Epirubicin—prostate cancer	1.94e-05	5.79e-05	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—PIK3CB—prostate cancer	1.94e-05	0.00011	CbGpPWpGaD
Octreotide—Vomiting—Doxorubicin—prostate cancer	1.92e-05	5.74e-05	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—PIK3CA—prostate cancer	1.92e-05	0.000109	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MDM2—prostate cancer	1.91e-05	0.000108	CbGpPWpGaD
Octreotide—Rash—Doxorubicin—prostate cancer	1.91e-05	5.69e-05	CcSEcCtD
Octreotide—Dermatitis—Doxorubicin—prostate cancer	1.91e-05	5.68e-05	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—GSK3B—prostate cancer	1.91e-05	0.000108	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MAP2K1—prostate cancer	1.9e-05	0.000108	CbGpPWpGaD
Octreotide—Headache—Doxorubicin—prostate cancer	1.9e-05	5.65e-05	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—PIK3CD—prostate cancer	1.89e-05	0.000107	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—ERBB2—prostate cancer	1.88e-05	0.000107	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—INS—prostate cancer	1.88e-05	0.000106	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—PIK3CA—prostate cancer	1.87e-05	0.000106	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—SERPINE1—prostate cancer	1.87e-05	0.000106	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CXCL8—prostate cancer	1.86e-05	0.000106	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PIK3CB—prostate cancer	1.86e-05	0.000105	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—KRAS—prostate cancer	1.85e-05	0.000105	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CREBBP—prostate cancer	1.84e-05	0.000104	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MYC—prostate cancer	1.84e-05	0.000104	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TGFB1—prostate cancer	1.83e-05	0.000104	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CDKN1B—prostate cancer	1.82e-05	0.000103	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IGF1—prostate cancer	1.82e-05	0.000103	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—FGF2—prostate cancer	1.81e-05	0.000103	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—EGFR—prostate cancer	1.81e-05	0.000102	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—AKT1—prostate cancer	1.8e-05	0.000102	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—EGFR—prostate cancer	1.8e-05	0.000102	CbGpPWpGaD
Octreotide—Nausea—Doxorubicin—prostate cancer	1.8e-05	5.36e-05	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—CXCL8—prostate cancer	1.79e-05	0.000101	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NOS3—prostate cancer	1.79e-05	0.000101	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CASP3—prostate cancer	1.78e-05	0.000101	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IL2—prostate cancer	1.78e-05	0.000101	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—IL6—prostate cancer	1.77e-05	0.0001	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MAP2K1—prostate cancer	1.76e-05	9.95e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3CD—prostate cancer	1.75e-05	9.89e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CDKN1B—prostate cancer	1.74e-05	9.88e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—JAK2—prostate cancer	1.74e-05	9.83e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CCND1—prostate cancer	1.74e-05	9.83e-05	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—PIK3CA—prostate cancer	1.73e-05	9.79e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—SERPINE1—prostate cancer	1.73e-05	9.78e-05	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—AKT1—prostate cancer	1.73e-05	9.77e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CTNNB1—prostate cancer	1.72e-05	9.74e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CASP3—prostate cancer	1.71e-05	9.68e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—KRAS—prostate cancer	1.71e-05	9.68e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—IL2—prostate cancer	1.71e-05	9.67e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—PIK3CA—prostate cancer	1.7e-05	9.64e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—IL6—prostate cancer	1.7e-05	9.62e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—KRAS—prostate cancer	1.7e-05	9.61e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MDM2—prostate cancer	1.69e-05	9.6e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MMP9—prostate cancer	1.69e-05	9.55e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CDKN1A—prostate cancer	1.68e-05	9.51e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PTEN—prostate cancer	1.68e-05	9.49e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—FGF2—prostate cancer	1.67e-05	9.47e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—ERBB2—prostate cancer	1.67e-05	9.46e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CCND1—prostate cancer	1.66e-05	9.43e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PIK3CB—prostate cancer	1.65e-05	9.34e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NOS3—prostate cancer	1.65e-05	9.34e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CTNNB1—prostate cancer	1.65e-05	9.33e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—AKT1—prostate cancer	1.63e-05	9.26e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MMP9—prostate cancer	1.62e-05	9.15e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CDKN1A—prostate cancer	1.61e-05	9.12e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PTEN—prostate cancer	1.61e-05	9.1e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—JAK2—prostate cancer	1.6e-05	9.07e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EP300—prostate cancer	1.6e-05	9.05e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CXCL8—prostate cancer	1.58e-05	8.97e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—PIK3CA—prostate cancer	1.57e-05	8.89e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—AKT1—prostate cancer	1.57e-05	8.88e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MDM2—prostate cancer	1.56e-05	8.86e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PIK3CA—prostate cancer	1.56e-05	8.83e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—SRC—prostate cancer	1.55e-05	8.8e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CDKN1B—prostate cancer	1.55e-05	8.76e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—ERBB2—prostate cancer	1.54e-05	8.73e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EP300—prostate cancer	1.53e-05	8.68e-05	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—AKT1—prostate cancer	1.53e-05	8.67e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3CB—prostate cancer	1.52e-05	8.62e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CASP3—prostate cancer	1.52e-05	8.59e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IL2—prostate cancer	1.51e-05	8.58e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—VEGFA—prostate cancer	1.51e-05	8.57e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TP53—prostate cancer	1.51e-05	8.55e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—IL6—prostate cancer	1.51e-05	8.53e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—STAT3—prostate cancer	1.5e-05	8.49e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—SRC—prostate cancer	1.49e-05	8.44e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CCND1—prostate cancer	1.48e-05	8.36e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CXCL8—prostate cancer	1.46e-05	8.28e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CTNNB1—prostate cancer	1.46e-05	8.28e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—VEGFA—prostate cancer	1.45e-05	8.22e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—STAT3—prostate cancer	1.44e-05	8.14e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MMP9—prostate cancer	1.43e-05	8.12e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CDKN1B—prostate cancer	1.43e-05	8.09e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CDKN1A—prostate cancer	1.43e-05	8.09e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PTEN—prostate cancer	1.42e-05	8.07e-05	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—AKT1—prostate cancer	1.41e-05	8e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CASP3—prostate cancer	1.4e-05	7.93e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IL2—prostate cancer	1.4e-05	7.91e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MYC—prostate cancer	1.39e-05	7.89e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—IL6—prostate cancer	1.39e-05	7.87e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—AKT1—prostate cancer	1.39e-05	7.87e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TGFB1—prostate cancer	1.39e-05	7.87e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—IL6—prostate cancer	1.38e-05	7.82e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CCND1—prostate cancer	1.36e-05	7.71e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EGFR—prostate cancer	1.36e-05	7.71e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EP300—prostate cancer	1.36e-05	7.69e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CTNNB1—prostate cancer	1.35e-05	7.64e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MYC—prostate cancer	1.34e-05	7.56e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TGFB1—prostate cancer	1.33e-05	7.54e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MMP9—prostate cancer	1.32e-05	7.49e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—SRC—prostate cancer	1.32e-05	7.48e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CDKN1A—prostate cancer	1.32e-05	7.46e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PTEN—prostate cancer	1.31e-05	7.45e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EGFR—prostate cancer	1.31e-05	7.39e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—VEGFA—prostate cancer	1.29e-05	7.29e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—KRAS—prostate cancer	1.29e-05	7.29e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—AKT1—prostate cancer	1.28e-05	7.26e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—STAT3—prostate cancer	1.27e-05	7.22e-05	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—AKT1—prostate cancer	1.27e-05	7.22e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—EP300—prostate cancer	1.25e-05	7.1e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—KRAS—prostate cancer	1.23e-05	6.99e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—SRC—prostate cancer	1.22e-05	6.91e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—VEGFA—prostate cancer	1.19e-05	6.73e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MYC—prostate cancer	1.18e-05	6.71e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PIK3CA—prostate cancer	1.18e-05	6.69e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TGFB1—prostate cancer	1.18e-05	6.69e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—STAT3—prostate cancer	1.18e-05	6.66e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EGFR—prostate cancer	1.16e-05	6.56e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TP53—prostate cancer	1.14e-05	6.48e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PIK3CA—prostate cancer	1.13e-05	6.42e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TP53—prostate cancer	1.1e-05	6.21e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—KRAS—prostate cancer	1.09e-05	6.2e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MYC—prostate cancer	1.09e-05	6.19e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TGFB1—prostate cancer	1.09e-05	6.17e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—EGFR—prostate cancer	1.07e-05	6.05e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—IL6—prostate cancer	1.05e-05	5.93e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—KRAS—prostate cancer	1.01e-05	5.72e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PIK3CA—prostate cancer	1.01e-05	5.69e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—IL6—prostate cancer	1e-05	5.68e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TP53—prostate cancer	9.72e-06	5.51e-05	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—AKT1—prostate cancer	9.66e-06	5.47e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3CA—prostate cancer	9.28e-06	5.25e-05	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—AKT1—prostate cancer	9.26e-06	5.24e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TP53—prostate cancer	8.97e-06	5.08e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IL6—prostate cancer	8.9e-06	5.04e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IL6—prostate cancer	8.21e-06	4.65e-05	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—AKT1—prostate cancer	8.21e-06	4.65e-05	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—AKT1—prostate cancer	7.58e-06	4.29e-05	CbGpPWpGaD
